Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) has launched its international NOBLE Registry of its prostate cancer imaging agent
- The NOBLE (Nobody Left Behind) registry collects data on the clinical use of TLX599- CDx, a product developed to facilitate patient access to advanced prostate cancer imaging
- The NOBLE registry will collect prospective, real-world clinical data on the use of the treatment from a number of sites in eight countries
- The company says it anticipates that this real-world data will facilitate the design of future formal registration clinical trials of the treatment
- Telix Pharmaceuticals is up 2.02 per cent, trading at $4.05
Telix Pharmaceuticals (TLX) has launched its international NOBLE Registry of its prostate cancer imaging agent.
The NOBLE (Nobody Left Behind), registry collects data on the clinical use of TLX599- CDx, an investigational product being developed by Telix to facilitate patient access to advanced prostate cancer imaging in countries where single-photon emission computed tomography (SPECT) imaging is predominant in healthcare facilities.
The NOBLE registry will collect prospective, real-world clinical data on the use of the treatment from a number of sites in eight countries. Each site will conduct its own investigator-initiated clinical study of the treatment under a common protocol and will share the resulting data with the NOBLE registry.
The company says it anticipates that this real-world data will facilitate the design of future formal registration clinical trials of TLX599- CDx.
“We are honoured to support the launch of the NOBLE Registry, which represents the very essence of our belief that every patient deserves access to the benefits of nuclear medicine,” said Telix Chief Executive Officer, Dr Christian Behrenbruch.
“Telix is committed to providing access to advanced prostate cancer imaging to all men across the globe and it is fitting that this excellent technology, developed at the Instituto Nacional de Investigaciones Nucleares (ININ, Mexico), will play a part in delivering this objective.”
Telix Pharmaceuticals is up 2.02 per cent on the back of this news, trading at $4.05 at 12:55 pm AEST.
